Travere CEO sells 400K shares after option exercise
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Travere Therapeutics, Inc. (TVTX) reported that Chief Executive Officer and director Eric M. Dube exercised employee stock options for a total of 400,000 shares of common stock at an exercise price of $23.34 per share on September 15–17, 2026, and sold 400,000 shares of common stock in open-market transactions on the same dates. The sales were made under a written trading plan adopted on June 16, 2026, that meets Rule 10b5-1(c) requirements, and the options exercised were fully vested and exercisable.
Insider Trade Summary 10b5-1
Exercise and Sale: 400,000 shares ($16.05M approx. pre-tax spread)
Exercise and Sale
14 txns
Insider
Dube Eric M
Role
CHIEF EXECUTIVE OFFICER
Sold
400,000 shs ($25.39M)
Approx. gross sale proceeds
$25.39M
Approx. exercise cost
$9.34M
Approx. pre-tax spread
$16.05M
Share of Position Sold
48.0%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee stock option (right to buy) F9 | 108,493 | $0.00 | $0.00 |
| Exercise | Common Stock | 108,493 | $23.34 | $2.53M |
| Sale | Common Stock F1, F7 | 101,691 | $64.5866 | $6.57M |
| Sale | Common Stock F1, F8 | 6,802 | $64.9508 | $442K |
| Exercise | Employee stock option (right to buy) F9 | 195,841 | $0.00 | $0.00 |
| Exercise | Common Stock | 195,841 | $23.34 | $4.57M |
| Sale | Common Stock F1, F5 | 99,716 | $63.2593 | $6.31M |
| Sale | Common Stock F1, F6 | 96,125 | $63.6389 | $6.12M |
| Exercise | Employee stock option (right to buy) F9 | 95,666 | $0.00 | $0.00 |
| Exercise | Common Stock | 95,666 | $23.34 | $2.23M |
| Sale | Common Stock F1, F2 | 63,498 | $61.9945 | $3.94M |
| Sale | Common Stock F1, F3 | 28,796 | $62.6553 | $1.80M |
| Sale | Common Stock F1, F4 | 3,102 | $63.6434 | $197K |
| Sale | Common Stock F1 | 270 | $65.31 | $18K |
Holdings After Transaction:
Employee stock option (right to buy) — 0 contracts (Direct);
Common Stock — 432,886 shares (Direct)
Holdings Before and After:
Employee stock option (right to buy), 400,000 to 0 contracts (Direct);
Common Stock, 432,886 to 432,886 shares (Direct)
Other Insiders: 8 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (9)
- F1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2. The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F3. The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4. The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5. The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F6. The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F7. The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F8. The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F9. The stock option is fully vested and exercisable.
Key Figures
Options exercised: 400,000 shares
Shares sold: 400,000 shares
Option exercise price: $23.34 per share
+4 more
7 metrics
Options exercised
400,000 shares
Total employee stock options exercised into common stock on September 15–17, 2026
Shares sold
400,000 shares
Total Travere Therapeutics common shares sold on September 15–17, 2026
Option exercise price
$23.34 per share
Exercise price for employee stock options converted into common stock
Weighted average sale price
$61.9945 per share
One of the reported weighted average sale prices with a range of $61.405–$62.40
Highest weighted average sale price
$64.9508 per share
Reported weighted average price for one transaction, range $64.84–$65.14
Option expiration date
January 4, 2029
Expiration date of the employee stock options that were exercised
Rule 10b5-1 plan adoption date
June 16, 2026
Date the written trading plan governing the sales was adopted
Key Terms
Rule 10b5-1(c), Employee stock option (right to buy), weighted average sale price, Common Stock
4 terms
Rule 10b5-1(c) regulatory
"written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
Employee stock option (right to buy) financial
"security titled Employee stock option (right to buy) was exercised into common stock"
weighted average sale price financial
"The weighted average sale price for the transaction reported was $61.9945"
Common Stock financial
"underlying security title for the options exercised was Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did TVTX report for its CEO in this Form 4?
The CEO, Eric M. Dube, exercised 400,000 stock options at $23.34 per share and sold 400,000 shares of Travere Therapeutics common stock in open-market transactions on September 15–17, 2026.
What was the exercise price of the Travere Therapeutics (TVTX) stock options exercised?
The employee stock options exercised by the CEO in September 2026 had an exercise price of $23.34 per share, with each exercise converting options into an equal number of Travere Therapeutics common shares.
Were the Travere Therapeutics stock options exercised by the CEO vested?
Yes. A footnote states that the stock option is fully vested and exercisable, indicating the CEO exercised already-vested employee stock options into common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
